Impact of hyperkalaemia on renin–angiotensin–aldosterone (RAAS) inhibitor reduction or withdrawal following hospitalisation
RAASi cessation was greater with hyperkalaemia and associated with increased mortality in hospitalised patients. Reinstitution of RAASi after hospital discharge, or alternative management of hyperkalaemia if maintained on RAASi therapy, may improve clinical outcomes.
Authors
- Philip A. Kelly (ORCID: https://orcid.org/0000-0003-4338-6225)
- Mohammad Al-Agil (ORCID: https://orcid.org/0000-0001-6292-9657)
- James Teo (ORCID: https://orcid.org/0000-0002-6899-8319)
- Claire C. Sharpe (ORCID: https://orcid.org/0000-0003-1704-8492)
- Hugh Logan Ellis (ORCID: https://orcid.org/0000-0002-6428-0158)
- Martin Whyte (ORCID: https://orcid.org/0000-0002-2897-2026)
Institutions
- University of Nottingham (GB)
- King's College London (GB)
- University of Surrey (GB)
- King's College Hospital NHS Foundation Trust (GB)
Publication Details
- Journal
- Clinical and Experimental Medicine
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1007/s10238-024-01531-9
- Citations
- 1
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- AstraZeneca